Aug 14 (Reuters) - Eli Lilly ( LLY ) has signed a deal
worth up to $1.3 billion with privately held Superluminal
Medicines to discover and develop drugs targeting
cardiometabolic diseases and obesity, Superluminal said on
Thursday.